RealClearInvestigations on MSN

Waste of the day: Autism Medicaid misspending

Topline: The Department of Health and Human Services’ inspector general identified $200 million in improper payments that Medicaid made for autism services between 2019 and 2024 in Maine, Indiana, ...
Las Vegas, NV - May 05, 2026 - PRESSADVANTAGE - Dr. Andrea Adams-Miller, neuroscientist, executive advisor, and CEO of ...
Welcome back to Diagnosis, a vertical focused on the intersection of healthcare policy and politics. — ‘Freedom’ battle — ...
Applied Behavior Analysis (ABA) is transforming how educators and clinicians support learners with diverse needs, from autism interventions to strategies for academic engagement. Universities such as ...
With 50 years of clinical experience, a Duke U. Ph.D. in Clinical Psychology, I am an empathic, results-oriented psychologist. Some of my specialties: relationships, anxiety, depression, stress ...
RALEIGH — State lawmakers say the cost for applied behavioral analysis is rising. That’s an autism care service typically for children. In fiscal year 2021 to 2022, $121.7 million in state and federal ...
WASHINGTON, Feb 11 (Reuters) - The U.S. Department of Commerce on Wednesday announced a $252 million settlement with Applied Materials (AMAT.O), opens new tab for illegally exporting chipmaking ...
In this guide to the canine adolescent years, Christopher Pachel, DVM, DACVB, CABC (IAABC), breaks down this critical phase—from hormones to the prefrontal cortex—based on his 2026 VMX session in ...
Beginning February 2, 2026, Single Assessment Referrals will be the required statewide process for determining eligibility for children’s medium- and high-intensity behavioral health services, under ...
Applied Digital boasts an exceptionally strong long-term demand visibility. The company is focused on rapidly expanding its data center capacity to meet surging demand. Applied Digital has also ...
Cycle Pharmaceuticals is circling up Applied Therapeutics, acquiring the rare disease biotech after an extremely tumultuous year for the latter that began with an FDA rejection at the end of 2024.